Ftse Mib
38.545,38
0,57%
DAX
22.828,95
0,14%
S&P 500
6.114,63
0,00%
NASDAQ
20.026,77
0,00%
Bitcoin
96.269,20
0,52%
Pepperstone
Advertisement
Registration Strip Icon for default Registrati gratuitamente per ottenere quotazioni in tempo reale, grafici interattivi, flusso di opzioni in tempo reale e altro ancora.
Registrati

Quotazioni in diretta

Non abbiamo trovato risultati per:
Assicurati di aver scritto correttamente o prova ad allargare la ricerca.

Più Attivi

Toplist

Sembra che tu non sia connesso.
Clicca il pulsante qui sotto per accedere e visualizzare la tua cronologia recente.

Registrati

Sei già registrato? Accedi

Pepperstone

Inizia Ora

Pepperstone
Home Investire Azioni U.S.A. NASDAQ CervoMed Inc (CRVO) CervoMed Inc (CRVO) Notizie

CRVO

CervoMed (CRVO)

HOME News News di Agenzia

News di Agenzia

Da:
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CRVO
DataOraFonteTitoloSimboloCompagnia
15/02/202500:28Edgar (US Regulatory)Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:CRVOCervoMed Inc
15/02/202500:02Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CRVOCervoMed Inc
31/01/202514:18Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CRVOCervoMed Inc
31/01/202514:00GlobeNewswire Inc.CervoMed Provides Update on Neflamapimod DLB Program as Part of Presentation at the 8th International Lewy Body Dementia ConferenceNASDAQ:CRVOCervoMed Inc
29/01/202514:00GlobeNewswire Inc.CervoMed to Present at the 8th International Lewy Body Dementia ConferenceNASDAQ:CRVOCervoMed Inc
12/12/202413:00GlobeNewswire Inc.CervoMed Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)NASDAQ:CRVOCervoMed Inc
10/12/202413:00GlobeNewswire Inc.CervoMed Announces Topline Data from RewinD-LB Phase 2b Clinical Trial in Patients with Dementia with Lewy BodiesNASDAQ:CRVOCervoMed Inc
27/11/202413:00GlobeNewswire Inc.CervoMed Announces Orphan Drug Designation Granted to Neflamapimod by U.S. Food and Drug Administration for the Treatment of Frontotemporal DementiaNASDAQ:CRVOCervoMed Inc
14/11/202421:09Edgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:CRVOCervoMed Inc
13/11/202414:00GlobeNewswire Inc.CervoMed Announces Key Senior Leadership AppointmentsNASDAQ:CRVOCervoMed Inc
12/11/202413:00GlobeNewswire Inc.CervoMed Reports Third Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:CRVOCervoMed Inc
08/11/202415:55GlobeNewswire Inc.CervoMed Awarded the Prix Galien USA 2024 Prize for Best StartupNASDAQ:CRVOCervoMed Inc
07/11/202414:30GlobeNewswire Inc.CervoMed to Participate in Upcoming Investor ConferencesNASDAQ:CRVOCervoMed Inc
04/11/202414:00GlobeNewswire Inc.CervoMed Announces Key Takeaways from Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)NASDAQ:CRVOCervoMed Inc
29/10/202413:00GlobeNewswire Inc.CervoMed to Deliver Oral Presentation at the 8th International Lewy Body Dementia ConferenceNASDAQ:CRVOCervoMed Inc
15/10/202414:00GlobeNewswire Inc.CervoMed Announces Last Patient Last Visit in Phase 2b RewinD-LB Trial of Neflamapimod for the Treatment of Early-Stage Dementia with Lewy Bodies (DLB)NASDAQ:CRVOCervoMed Inc
11/10/202414:13Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CRVOCervoMed Inc
11/10/202406:15Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CRVOCervoMed Inc
03/10/202423:12Edgar (US Regulatory)Form S-3 - Registration statement under Securities Act of 1933NASDAQ:CRVOCervoMed Inc
03/10/202423:02Edgar (US Regulatory)Form POS AM - Post-Effective amendments for registration statementNASDAQ:CRVOCervoMed Inc
02/10/202414:00GlobeNewswire Inc.CervoMed to Participate in 3rd Annual ROTH Healthcare Opportunities ConferenceNASDAQ:CRVOCervoMed Inc
26/09/202414:00GlobeNewswire Inc.CervoMed to Deliver Late-Breaking Oral Presentations at the 17th Clinical Trials on Alzheimer's Disease Conference (CTAD)NASDAQ:CRVOCervoMed Inc
22/08/202414:00GlobeNewswire Inc.CervoMed Featured in Fortune for Advances in the Treatment of Dementia with Lewy BodiesNASDAQ:CRVOCervoMed Inc
12/08/202414:00GlobeNewswire Inc.CervoMed Reports Second Quarter 2024 Financial Results and Provides Corporate UpdatesNASDAQ:CRVOCervoMed Inc
30/07/202414:00GlobeNewswire Inc.CervoMed to Participate in The Canaccord Genuity 44th Annual Growth ConferenceNASDAQ:CRVOCervoMed Inc
29/07/202414:00GlobeNewswire Inc.CervoMed Announces Presentation at AAIC 2024 on Plasma Biomarker Data That Are Consistent with Neflamapimod Impacting the Underlying Disease Process in Patients with Dementia with Lewy bodies (DLB)NASDAQ:CRVOCervoMed Inc
17/07/202414:00GlobeNewswire Inc.CervoMed to Participate in the Emerging Growth ConferenceNASDAQ:CRVOCervoMed Inc
11/07/202414:51GlobeNewswire Inc.CervoMed to Host Virtual KOL Event on Neflamapimod for Dementia with Lewy Bodies on July 23, 2024NASDAQ:CRVOCervoMed Inc
24/06/202414:00GlobeNewswire Inc.CervoMed Announces Addition to Russell 2000® and Russell 3000® IndexesNASDAQ:CRVOCervoMed Inc
11/06/202414:00GlobeNewswire Inc.CervoMed Announces Completion of Enrollment in Phase 2b RewinD-LB Clinical Trial of Neflamapimod for the Treatment of Patients with Dementia with Lewy BodiesNASDAQ:CRVOCervoMed Inc
 Ti mostriamo gli articoli più rilevanti per la tua ricerca:NASDAQ:CRVO

La tua Cronologia

BIT
F13403
Vontobel Financial Produ...
BIT
UR9Z1B
UniCredit Bank
BIT
UC3S8Y
Unicredit Bank
NYSE
BILL
BILL
ASX
OARN
Oakdale Resources
Delayed Upgrade Clock
Per accedere al tempo reale push di Borsa è necessario registrarsi.

Il sito ADVFN Italia è stato realizzato ed è gestito da PRODESFIN su licenza di ADVFN PLC.

PER CONTATTI E PUBBLICITA' SUL SITO CLICCARE QUI

Accedendo ai servizi offerti da ADVFN, ne si accettano le condizioni generali Termini & Condizioni

ADVFN Network

Rimuovi gli annunci

Iscriviti per un'esperienza senza pubblicità

Nessuna pubblicità

Prova adesso

Conserva gli annunci